Polyphenol-Armored Hydrogel Reverses Chondrocyte Senescence in Aged Osteoarthritis

Osteoarthritis (OA) is the most prevalent age-related joint disease, affecting the majority of adults over 65, yet no approved therapy halts its progression. The central problem is chondrocyte senescence: aging cartilage cells accumulate DNA damage, mitochondrial dysfunction, and oxidative stress, triggering a senescence-associated secretory phenotype (SASP) that floods the joint with pro-inflammatory cytokines and proteases. MicroRNA-140 (miR-140) is a critical endogenous regulator of cartilage homeostasis whose expression is markedly reduced in aged OA patients; restoring it silences the PI3K-p53 senescence axis, suppresses ECM degradation, and blocks chondrocyte hypertrophy. Delivering miR-140 intra-articularly has historically failed because the molecule degrades rapidly in the RNase- and ROS-rich joint environment and is cleared within hours through vascular and lymphatic drainage.

To overcome these barriers, the team fabricated polyphenol-armored nanoparticles (nMSN@140-(PFe/CSWY)₃) using a layer-by-layer assembly on amino-functionalized mesoporous silica nanoparticles (nMSN, ~100 nm). miR-140 was loaded electrostatically into the positively charged nMSN core, then three alternating bilayers of polydopamine-iron (PFe) and WYRGRL-peptide-modified chitosan (CSWY) were deposited, producing a ~15 nm shell. Zeta potential measurements confirmed alternating surface charge inversion at each deposition step, and X-ray photoelectron spectroscopy (XPS) verified catechol/quinone-iron redox pairs in the PFe layers. Encapsulation efficiency for FAM-labeled miR-140 reached high levels, and agarose gel retardation assays showed the armor fully retained miR-140 during incubation with RNase, whereas uncoated nanoparticles degraded rapidly. H₂O₂ and superoxide scavenging assays demonstrated catalase- and superoxide dismutase-like enzymatic activity attributable to the iron-catechol pairs.

The nanoparticles were embedded in a dual-polymer hydrogel matrix formed by mixing oxidized hyaluronic acid modified with dopamine (OHA-DA) and hydrazide-modified hyaluronic acid (HA-ADH). Dynamic acylhydrazone crosslinks give the gel shear-thinning injectability, while pH-sensitive imine bonds between OHA-DA aldehydes and nanoparticle amino groups create an acid-responsive release mechanism matched to the acidic senescence microenvironment (pH ~6.5). Catechol groups in both OHA-DA and the PFe armor confer tissue bioadhesion to cartilage surfaces, and the carboxylate backbone of hyaluronic acid generates a hydration lubrication layer. Tribological testing showed significantly reduced coefficients of friction compared with saline controls, while adhesion peel tests confirmed superior cartilage attachment relative to non-catechol hydrogels.

In vitro, senescent chondrocytes treated with nMSN@140-(PFe/CSWY)₃ showed markedly reduced SA-β-galactosidase activity, decreased p21 and p53 protein expression, and restored collagen II and aggrecan production compared with untreated senescent cells and miR-140 administered without the armor. Confocal imaging demonstrated efficient lysosomal escape and nuclear miR-140 delivery. Mitochondrial membrane potential was rescued and mtROS levels fell, consistent with the enzymatic antioxidant activity of the PFe layer. In an aged rat OA model (surgically induced via ACLT in 18-month-old rats), a single intra-articular injection of the full hydrogel system preserved cartilage thickness, reduced OARSI histological scores, lowered synovial p16/p21 immunostaining, and decreased MMP-13 and ADAMTS-5 protease expression significantly more than free miR-140, nanoparticles alone, or hydrogel without nanoparticles, with effects sustained over the 8-week observation period.

The study represents a meaningful conceptual advance in treating age-driven OA by simultaneously addressing mechanical stress (lubrication), oxidative stress (enzymatic ROS scavenging), and genetic dysregulation (sustained miR-140 delivery) within a single injectable platform. Clinical translation will require demonstration in larger animal models, long-term safety profiling of iron-polyphenol degradation products, and eventual pharmacokinetic studies in humans. The preclinical data nevertheless establish a strong proof-of-concept that rejuvenating chondrocyte senescence—rather than merely managing symptoms—is an achievable therapeutic target.